# Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

> **NCT06077773** · PHASE2 · TERMINATED · sponsor: **Escient Pharmaceuticals, Inc** · enrollment: 113 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** Oral EP262
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06077773
- **Lead sponsor:** Escient Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-25
- **Primary completion:** 2024-12-18
- **Final completion:** 2025-01-16
- **Target enrollment:** 113 (ACTUAL)
- **Why stopped:** Strategic Business Decision
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06077773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06077773, "Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06077773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*